- $797.40m
- $767.39m
- $407.32m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 18.99 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.35 | ||
| Price to Tang. Book | 5.35 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.77 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -7.99% | ||
| Return on Equity | -38.61% | ||
| Operating Margin | -7.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 10.1 | 52.16 | 124.46 | 333.62 | 407.32 | 487.16 | 623.24 | 121.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas.
Directors
- David Mott NEC (55)
- Michael Raab PRE (56)
- Justin Renz CFO (49)
- Elizabeth Grammer CAD (57)
- Jeffrey Jacobs CSO (57)
- Robert Blanks OTH (61)
- Susan Rodriguez OTH (57)
- David Rosenbaum OTH (60)
- Robert Bazemore IND (53)
- William Bertrand IND (56)
- Muna Bhanji IND (58)
- Geoffrey Block IND (55)
- Onaiza Cadoret-Manier IND (57)
- Jan Lundberg IND (66)
- Richard Rodgers IND (54)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- October 18th, 2007
- Public Since
- June 19th, 2014
- No. of Shareholders
- 23
- No. of Employees
- 489
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 249,187,572
- Address
- 400 Fifth Avenue, Suite 210, WALTHAM, 02451
- Web
- https://www.ardelyx.com/
- Phone
- +1 3026974590
- Auditors
- Ernst & Young LLP
Latest News for ARDX
Upcoming Events for ARDX
Q3 2026 Ardelyx, Inc. Earnings Release
Q3 2026 Ardelyx, Inc. Earnings Call
Similar to ARDX
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
As of Today at 01:20 UTC, shares in Ardelyx are trading at $3.20. This share price information is delayed by 15 minutes.
Shares in Ardelyx last closed at $3.20 and the price had moved by -37.86% over the past 365 days. In terms of relative price strength the Ardelyx share price has underperformed the S&P500 Index by -45.36% over the past year.
The overall consensus recommendation for Ardelyx is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreArdelyx does not currently pay a dividend.
Ardelyx does not currently pay a dividend.
Ardelyx does not currently pay a dividend.
To buy shares in Ardelyx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.20, shares in Ardelyx had a market capitalisation of $797.40m.
Here are the trading details for Ardelyx:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ARDX
Based on an overall assessment of its quality, value and momentum Ardelyx is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Ardelyx is $12.88. That is 302.5% above the last closing price of $3.20.
Analysts covering Ardelyx currently have a consensus Earnings Per Share (EPS) forecast of -$0.18 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ardelyx. Over the past six months, its share price has underperformed the S&P500 Index by -49.65%.
As of the last closing price of $3.20, shares in Ardelyx were trading -41.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ardelyx PE ratio based on its reported earnings over the past 12 months is 18.99. The shares last closed at $3.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Ardelyx's management team is headed by:
- David Mott - NEC
- Michael Raab - PRE
- Justin Renz - CFO
- Elizabeth Grammer - CAD
- Jeffrey Jacobs - CSO
- Robert Blanks - OTH
- Susan Rodriguez - OTH
- David Rosenbaum - OTH
- Robert Bazemore - IND
- William Bertrand - IND
- Muna Bhanji - IND
- Geoffrey Block - IND
- Onaiza Cadoret-Manier - IND
- Jan Lundberg - IND
- Richard Rodgers - IND